Detailed Mechanism Funding and Narrative

Years of mechanism: 2010 2011 2012 2013 2014 2015 2016 2017

Details for Mechanism ID: 7241
Country/Region: Tanzania
Year: 2016
Main Partner: PharmAccess Foundation
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: USDOD
Total Funding: $4,440,774 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $464,431
Care: Orphans and Vulnerable Children (HKID) $37,267
Care: TB/HIV (HVTB) $87,985
Care: Pediatric Care and Support (PDCS) $17,364
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $500,172
Testing: HIV Testing and Counseling (HVCT) $249,067
Sexual Prevention: Other Sexual Prevention (HVOP) $36,000
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $251,449
Treatment: Adult Treatment (HTXS) $2,654,356
Treatment: Pediatric Treatment (PDTX) $142,683
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST Age/sex: <1 2017 262
HTS_TST Age/sex: 1-9 2017 1,241
HTS_TST Age/sex: 10-14 Female 2017 319
HTS_TST Age/sex: 10-14 Male 2017 574
HTS_TST Age/sex: 15-19 Female 2017 501
HTS_TST Age/sex: 15-19 Male 2017 455
HTS_TST Age/sex: 20-24 Female 2017 746
HTS_TST Age/sex: 20-24 Male 2017 394
HTS_TST Age/sex: 25-49 Female 2017 2,771
HTS_TST Age/sex: 25-49 Male 2017 1,305
HTS_TST Age/sex: 50+ Female 2017 610
HTS_TST Age/sex: 50+ Male 2017 574
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 11,764
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 16,352
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 45,114
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 23,489
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 106,471
HTS_TST Service Delivery Point (Community): Homebased testing 2017 7,582
HTS_TST Service Delivery Point (Community): Mobile testing 2017 17,946
HTS_TST Service Delivery Point (Facility): Inpatient 2017 3,036
HTS_TST Service Delivery Point (Facility): Other PITC 2017 2,718
HTS_TST Service Delivery Point (Facility): Outpatient 2017 32,185
HTS_TST Service Delivery Point (Facility): Pediatric 2017 15,091
HTS_TST Service Delivery Point (Facility): PMTCT 2017 15,081
HTS_TST Service Delivery Point (Facility): VMMC 2017 12,832
HTS_TST Sum of Age/Sex disaggregates 2017 8,249
HTS_TST Sum of Aggregated Age/Sex <15 2017 28,116
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 68,603
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 96,719
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Female 2017 32
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Male 2017 28
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Female 2017 43
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Male 2017 22
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Female 2017 91
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Male 2017 26
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Female 2017 210
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Male 2017 96
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Female 2017 52
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Male 2017 45
HTS_TST_POS Test Result by Age: Positive: <1 2017 3
HTS_TST_POS Test Result by Age: Positive: 1-9 2017 39
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 252
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 362
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 2,891
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 1,875
LAB_PT CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 22
LAB_PT CD4: Number of laboratories that participate in this PT program 2017 22
LAB_PT CD4: Number of laboratories that perform this testing 2017 22
LAB_PT Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 29
LAB_PT Early infant diagnostics: Number of laboratories that participate in this PT program 2017 26
LAB_PT Early infant diagnostics: Number of laboratories that perform this testing 2017 26
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 46
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2017 49
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2017 49
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 25
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program 2017 25
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that perform this testing 2017 25
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 5
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program 2017 5
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing 2017 5
OVC_SERV Age/Sex: 18+ Female 2017 90
OVC_SERV Age/Sex: 18+ Male 2017 57
OVC_SERV By Aggregated Age/Sex: <18 Female 2017 543
OVC_SERV By Aggregated Age/Sex: <18 Male 2017 360
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2017 1,050
OVC_SERV Sum of Age/Sex disaggregates 2017 147
PMTCT_ART Already on ART at beginning of current pregnancy 2017 241
PMTCT_ART New on ART 2017 554
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 14,183
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 666
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 127
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 7
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 13
PMTCT_EID Sum of Infant Age disaggregates 2017 793
PMTCT_STAT By: Known positives at entry 2017 254
PMTCT_STAT By: Number of new positives identified 2017 583
PMTCT_STAT Number of new ANC and L&D clients 2017 15,306
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 14,183
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: <15 2017 1
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 15-19 2017 3
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 20-24 2017 8
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 25-49 2017 18
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: <15 2017 2
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 15-19 2017 7
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 20-24 2017 15
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 25-49 2017 34
PMTCT_STAT Sum of Positives Status disaggregates 2017 837
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: <15 2017 43
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: <15-19 2017 116
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 20-24 2017 284
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 25-49 2017 712
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 50+ 2017 10
PP_PREV Aggregated Age/sex: <15 Female 2017 230
PP_PREV Aggregated Age/sex: 15+ Female 2017 770
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2017 1,000
PP_PREV Total number of people in the target population 2017 19,922
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 366
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 9
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 320
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 37
TB_SCREENDX Screen Result: Screened Positive for TB 2017 366
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 15,326
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 6,050
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 637
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 613
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 22,626
TX_CURR Age/Sex: <1 2017 2
TX_CURR Age/Sex: <1-9 2017 46
TX_CURR Age/Sex: 10-14 Female 2017 11
TX_CURR Age/Sex: 10-14 Male 2017 14
TX_CURR Age/Sex: 15-19 Female 2017 71
TX_CURR Age/Sex: 15-19 Male 2017 38
TX_CURR Age/Sex: 20-24 Female 2017 121
TX_CURR Age/Sex: 20-24 Male 2017 9
TX_CURR Age/Sex: 25-49 Female 2017 564
TX_CURR Age/Sex: 25-49 Male 2017 167
TX_CURR Age/Sex: 50+ Female 2017 58
TX_CURR Age/Sex: 50+ Male 2017 48
TX_CURR Aggregated Age/Sex: <15 Female 2017 655
TX_CURR Aggregated Age/Sex: <15 Male 2017 691
TX_CURR Aggregated Age/Sex: 15+ Female 2017 15,723
TX_CURR Aggregated Age/Sex: 15+ Male 2017 5,597
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 23,815
TX_CURR Sum of age/sex disaggregates 2017 109
TX_CURR Sum of Aggregated Age/Sex <15 2017 1,346
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 21,320
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 22,666
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 227
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 245
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 4,420
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 1,584
TX_NEW By Age/Sex: <1 2017 2
TX_NEW By Age/Sex: 1-9 2017 15
TX_NEW By Age/Sex: 10-14 Female 2017 4
TX_NEW By Age/Sex: 10-14 Male 2017 3
TX_NEW By Age/Sex: 15-19 Female 2017 39
TX_NEW By Age/Sex: 15-19 Male 2017 20
TX_NEW By Age/Sex: 20-24 Female 2017 51
TX_NEW By Age/Sex: 20-24 Male 2017 4
TX_NEW By Age/Sex: 25-49 Female 2017 221
TX_NEW By Age/Sex: 25-49 Male 2017 87
TX_NEW By Age/Sex: 50+ Female 2017 25
TX_NEW By Age/Sex: 50+ Male 2017 23
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 6,970
TX_NEW Sum of Age/Sex disaggregates 2017 477
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 6,476
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 14,244
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 12,834
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 413
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 433
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 8,697
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 3,291
TX_PVLS Numerator: Indication: Routine 2017 6,281
TX_PVLS Numerator: Indication: Targeted 2017 6,553
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 454
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 478
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 9,656
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 3,656
TX_PVLS_den Denominator: Indication: Routine 2017 6,970
TX_PVLS_den Denominator: Indication: Targeted 2017 7,274
TX_RET Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 3
TX_RET Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1
TX_RET Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 15
TX_RET Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 7
TX_RET Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 17
TX_RET Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1
TX_RET Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 72
TX_RET Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 32
TX_RET Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 9
TX_RET Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 9
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 76
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 70
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,152
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 492
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 1,956
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 2,623
TX_RET_den Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2
TX_RET_den Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 4
TX_RET_den Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1
TX_RET_den Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1
TX_RET_den Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 19
TX_RET_den Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 10
TX_RET_den Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 23
TX_RET_den Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2
TX_RET_den Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 97
TX_RET_den Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 42
TX_RET_den Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 12
TX_RET_den Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 12
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 105
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 98
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,533
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 662
VMMC_CIRC By Age: 10-14 2017 6,416
VMMC_CIRC By Age: 15-19 2017 3,917
VMMC_CIRC By Age: 20-24 2017 864
VMMC_CIRC By Age: 25-29 2017 1,635
VMMC_CIRC By circumcision technique: Surgical VMMC 2017 12,832
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2017 12,832
VMMC_CIRC Sum of age disaggregates (FY15-Current) 2017 12,832
VMMC_CIRC Sum of age disaggregates (Prior to FY15) 2017 11,197